Neurodegenerative Disease

People and Culture

In neuroscience, “an inflection point in knowledge and technology”

Drug DiscoveryNeurodegenerative DiseaseNeuroscienceNovartis Institutes for BioMedical ResearchScientific Research
New Novartis extension phase data show nearly 80% of RMS patients treated with Kesimpta® (ofatumumab) had no evidence of disease activity (NEDA-3)

Basel, June 27, 2022 — Novartis today announced new data from the Phase 3 ASCLEPIOS I/II trials and the ALITHIOS open-label extension showing continuous treatment with Kesimpta® (ofatumumab) significantly increased the odds of achieving no evidence of disease activity (NEDA-3) versus switching from teriflunomide1. These data were presented at the…

NeuroscienceNeurodegenerative Disease
Novartis presents new four-year data on efficacy and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosis

Basel, April 5, 2022 — Novartis today announced new long-term data from the Phase 3 ASCLEPIOS I/II trials and the ALITHIOS open-label extension that demonstrated long-term efficacy and safety of Kesimpta® (ofatumumab), with continued reduced risk of disability worsening, for people living with relapsing multiple sclerosis following up to four…

NeuroscienceNeurodegenerative Disease
Novartis announces U.S. Court of Appeals for the Federal Circuit (CAFC) upholds validity of Gilenya® (fingolimod) dosage regimen patent

Basel, January 4, 2022 — Today, Novartis announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) issued its decision upholding the validity of US Patent No. 9,187,405 covering a dosing regimen for Gilenya. In August 2020, the U.S. Federal District Court for the District of Delaware issued a favorable decision in the Gilenya patent…

NeuroscienceNeurodegenerative Disease
Novartis, Voyager Therapeutics reach license option agreement for next-generation gene therapy vectors for neurological diseases

Basel, March 8, 2022 — Novartis today announced a license option agreement with Voyager Therapeutics, a gene therapy company focused on next-generation adeno-associated virus (AAV) technologies, for three capsids to use in potential gene therapies for neurological diseases, with options to access capsids for two other targets.

Scientific ResearchNeuroscienceNeurodegenerative Disease
New peer-reviewed research shows no increased risk of serious COVID-19 infections in Kesimpta® (ofatumumab)-treated adults with multiple sclerosis

Basel, March 18, 2022 — Novartis today announced that the peer-reviewed journal Neurology and Therapy1 has published new data on COVID-19 infections in people living with relapsing multiple sclerosis (RMS) treated with Kesimpta® (ofatumumab). This data was compiled from the ongoing, open-label, long-term extension phase 3b ALITHIOS study and from…

NeuroscienceNeurodegenerative Disease
Kesimpta® (ofatumumab) data at ECTRIMS highlights preservation of IgG levels and safety experience over extended exposure (~3.5 years) in people living with relapsing multiple sclerosis

Basel, October 14, 2021 — Today, Novartis announced data demonstrating the safety of Kesimpta® (ofatumumab) over extended exposure (~3.5 years) in patients with relapsing forms of multiple sclerosis (RMS).1 These data—presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) taking place…

NeuroscienceNeurodegenerative Disease
Discovery

Using Super-Resolution Microscopy To See Neurodegeneration

Novartis data scientists are using super-resolution microscopy to see neurodegeneration the moment it starts.

Neurodegenerative DiseaseNeuroscienceNovartis Institutes for BioMedical ResearchScientific ResearchAlzheimer’s disease
Patient Perspectives

Longevity with vitality: Japanese elders provide examples for healthy aging

Ogimi in Okinawa, Japan has the highest percentage of centenarians in the world, making it a curiosity for those eager to learn more about the secrets of aging.

Future of HealthcareMedical InnovationsNeurodegenerative Disease
Discovery

Tackling a rare disease: Working toward a treatment for SMA

Most people have never heard of spinal muscular atrophy (SMA), a rare genetic disease that affects approximately 1 in 6,000 babies born worldwide each year. Innovative research may produce treatments for patients suffering from SMA and other rare diseases.

Children's HealthGene SequencingInnovationNeurodegenerative DiseaseRare Diseases
From Our Labs

Neuroscientists target Alzheimer’s “silent stage”

Research exploring the first visible changes in the brain is helping scientists evaluate new potential treatments for Alzheimer’s.

Neurodegenerative DiseaseNeuroscienceClinical TrialsAlzheimer’s diseaseGene Testing
Discovery

Compound designed to fight Alzheimer’s disease shows promise in the lab

The molecule restores the activity of neurons and neural circuits in a model of the disease.

Drug DiscoveryNeurodegenerative DiseaseNovartis Institutes for BioMedical ResearchScientific ResearchAlzheimer’s disease